The aim of this study was to evaluate the pharmacogenetic role of the factor XIII (FXIII) valine 34 leucine (Val34Leu) polymorphism in the fibrinolytic therapy of acute myocardial infarction (MI). BACKGROUND Fibrinolytic therapy is an established treatment for acute MI, but up to 40% of treated patients do not achieve optimal tissue reperfusion. The FXIII Val34Leu polymorphism is one of the most relevant functional polymorphisms described in the haemostatic system. The common Leu34 allele associates with an increased FXIII-transglutaminase activity, which results in an increased and faster rate of fibrin stabilization.
Fibrinolytic therapy is used to achieve the most important objective in patients with an acute myocardial infarction (MI) , to open quickly the coronary flow after the occurrence of an acute coronary occlusion. Indeed, fibrinolytic therapy leads to better survival, recovery of left ventricular function, and remodelling following acute MI (1) (2) (3) . Unfortunately, approximately 40% of treated patients do not achieve optimal tissue perfusion (4), and the potential benefits are limited by early (thrombotic) re-occlusion of the infarctrelated artery (5) . However, few factors have been identified to be involved in this inter-individual heterogeneity, such as age, delay between symptom onset and fibrinolytic therapy, smoking habit, and infarct size or site (6, 7) .
Coagulation factor XIII (FXIII) is a tetrameric structure consisting of two A (active) and two B subunits. Calcium and thrombin activate factor XIII in the final phase of the coagulation process. Activated FXIII catalyzes the formation of covalent gamma-glutamyl-gamma-lysine bonds between fibrin monomers, increasing the resistance of fibrin to degradation by plasmin (8) . Multiple polymorphisms have been described in the FXIII-A subunit gene. A common G-to-T polymorphism in exon 2 causes a valine (Val) to leucine (Leu) change at position 34, three amino acids upstream to the thrombin cleavage site. This Val34Leu polymorphism affects the function of FXIII by increasing the rate of FXIII activation by thrombin, which results in an increased and faster rate of fibrin stabilization (9, 10) . However, the thrombotic role of this polymorphism is controversial and might be specific to populations (11) (12) (13) (14) .
In a small and retrospective cohort of survivors of premature MI, our group observed-for the first time-that Leu34 allele carriers could show more "resistance" to fibrinolytic therapy (15) . In the present report, we prospectively studied an unselected, consecutive cohort of acute MI patients, eligible for fibrinolytic treatment, from two different European populations, and noninvasively assessed the efficacy of fibrinolytic therapy. Again, our hypothesis was that the presence of the Leu34 allele reduces the clinical efficacy of fibrinolytic therapy for acute MI. Indo-Asians) and 123 from Hospital General Universitario, Alicante, Spain (all white Caucasian), who were eligible for fibrinolytic therapy. Both are University tertiary hospitals with 800 and 915 beds, respectively. Although at the time of this study there was no formal primary percutaneous coronary intervention (PCI) program for acute MI in both hospitals, about 88 patients were not included in the present study as primary PCIs were performed. All recruited subjects gave their informed consent to enter the study, which had been approved by the local research committee and was performed in accordance with the Declaration of Helsinki, as amended in Edinburgh in 2000.
PATIENTS AND METHODS

Patients
Major cardiovascular risk factors (current smoking status, hypercholesterolemia, diabetes and hypertension) were recorded. Clinical features of patients and controls are indicated in Table 1 . All patients were treated with standard doses of fibrinolytic drugs (tenecteplase, n ϭ 199; streptokinase, n ϭ 87; and recombinant tissue plasminogen activator, n ϭ 9). Delay in initiation of fibrinolytic drugs from symptom onset was recorded.
Assessment of efficacy of fibrinolysis and outcome.
Noninvasive assessment of the efficacy of coronary fibrinolysis was evaluated by a combination of clinical assessment, serial electrocardiograms and creatine kinase (CK) time-activity curves. A 12-lead electrocardiogram was registered at 0, 30, 60, 90, 120, 180, 240, and 300 min after fibrinolysis initiation. Blood samples for CK determination were drawn at 0, 3, 6, 9, 12, 15, and 21 h after fibrinolysis initiation. A resolution of ST-segment elevation more than 50% at 90 min and an early peak of CK (Յ12 h) were considered as reperfusion criteria (16) . All electrocardiograms were reviewed by two investigators who had no knowledge of the genetic determinations. When electrocardiograms were considered not interpretable (four patients) the early peak of CK was considered as the unique reperfusion criteria. The efficacy of fibrinolysis and the clinical outcome were also re-evaluated at 24 h (death, reinfarction, or necessity of urgent PCI). Determination of FXIII Val34Leu genotype. Total genomic deoxyribonucleic acid was obtained from the white blood cell following the instruction of the Wizard genomic deoxyribonucleic acid purification system (Promega Innogenetics, Madrid, Spain). Genomic polymerase chain reaction of the FXIII-A chain exon 2 gene was performed with mutated primers, essentially as indicated elsewhere (17) . The FXIII genotype was established after restriction of the polymerase chain reaction product with Bsa HI (17) . Statistical analysis. Results are expressed as mean value Ϯ standard deviation for continuous variables and as percentages for categorical variables. Univariate statistical analysis was performed by the chi-square test. The strength of the association of the polymorphism with the occurrence of end points (reperfusion or clinical outcome at 24 h) was estimated by calculation of the odds ratio (OR) and the Cornfield method for the calculation of 95% confidence intervals (CIs). Multivariate analysis was performed using logistic regression, Enter method (adjusting by gender, age,
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RESULTS
Clinical characteristics and genetic frequencies are summarized in Table 1 . We did not detect any age or gender differences, and the distribution of genotypes was not significantly different from Hardy-Weinberg proportions (data not shown). The prevalence of the FXIII Val34Leu polymorphism in the different ethnic groups (Val/Leu ϩ Leu/Leu: Mediterranean Caucasians 35.0%; British Caucasians 44.0%; and Indo-Asians 29.5%) was broadly similar to that previously described (11) (12) (13) (14) 17) . Fibrinolytic therapy. In the univariate analysis, only the FXIII Val34Leu polymorphism was statistically associated with the efficacy of fibrinolytic therapy ( (Tables 2 and 3 ). Importantly, ethnicity did not have a significant influence on fibrinolytic efficacy or the 24-h outcome (Tables 2 and 3 ).
In the multivariate analysis (logistic regression), fibrinolysis in Leu34 allele patients was significantly less efficient than that achieved among patients carrying the Val/Val genotype (p ϭ 0.021, OR 1.90, 95% CI 1.10 to 3.28) ( Table 2 ). Re-evaluation at 24 h revealed that the FXIII Val34Leu polymorphism was the only factor displaying a significant role (p ϭ 0.006, OR 2.14, 95% CI 1.25 to 3.68) ( Table 3) .
Smoking habit did not significantly influence fibrinolytic therapy efficacy on a crude analysis ( Table 3 ), but after FXIII Polymorphism and Fibrinolytic Therapy adjustment for clinical variables, this was associated with a better outcome at 24 h (p ϭ 0.049). As previous observations have described a higher rate of reperfusion in smokers (18 -20) , we also analyzed the possible synergistic interaction between FXIII Val34Leu polymorphism and smoking habit. In a multivariate analysis, the simultaneous combination of Leu34 allele and nonsmoking status increased the risk to nonreperfusion (p ϭ 0.003, OR 3.77, 95% CI 1.55 to 9.16) and a worse outcome at 24 h (p ϭ 0.001, OR 4.55, 95% CI 1.89 to 10.97) ( Figs. 1A and 1B) .
DISCUSSION
Consistent studies have demonstrated that primary PCI may be the preferred reperfusion strategy in acute MI, with reduction in death, reinfarction, and stroke compared to fibrinolytic therapy (21) . Unfortunately, several features limit the availability of PCI in a significant proportion of patients (22) . Hence, renewed interest has arisen about initiatives that could improve the fibrinolytic efficacy, including pre-hospital fibrinolysis programs, new therapeutic agents (tenecteplase), or new pharmacological reperfusion strategies (e.g., half-dose fibrinolytic agent plus glycoprotein IIb/IIIa receptor blockade) (23) .
Pharmacogenetics has emerged as a new field in medicine that tries to identify gene variants able to explain the heterogeneity in patient response to a drug (24) . Polymorphisms affecting disposition, metabolism, transporters, or targets of the drug could modify the individual response to one therapy, and its side effects (25) . The present study explores the hypothesis that there is a genetic influence on fibrinolytic therapy efficacy, by analyzing the role of a common polymorphism that affects the target of fibrinolytic drugs. Only one recent study has analyzed the role of the C-1562T polymorphism affecting the promoter region of the matrix metalloproteinase-9 gene in the haemorrhagic transformation of stroke after fibrinolytic therapy in 61 patients, finding no significant effect (26) . Therefore, to the best of our knowledge, our study is the first prospective one supporting a significant pharmacogenetic effect of one polymorphism in fibrinolytic therapy.
The main finding of the present prospective study in two different European populations (including three ethnic groups-Mediterranean white Caucasians, British white Caucasians, and British Indo-Asians) is that FXIII Val34Leu polymorphism was independently associated with less efficient fibrinolysis for acute MI. Accordingly, Leu34 allele carriers had a two-fold risk to not achieve optimal reperfusion, as well as a worse outcome at 24 h. These results are similar to those observed in a previous small and retrospective cohort of survivors of premature MI (15) . All our results support the observation that the FXIII Val34Leu polymorphism could modify the therapeutic effect of fibrinolytic drugs, and this presumption is also supported by the biochemical and haemostatic effect of the FXIII Val34Leu polymorphism: the Leu34 allele associates with increased FXIII activation by thrombin, affecting the structure and resistance of the cross-linked fibrin clot (10) .
Additionally, our study suggests a synergistic effect between FXIII Val34Leu polymorphisms and smoking. The simultaneous combination of one Leu34 allele and nonsmokers significantly increases the risk of poorer efficacy of fibrinolysis and a worse 24-h outcome. Smoking habit has been demonstrated to modify the effect of fibrinolytic therapy, with the highest reperfusion rate in smokers (18 -20) . Different hypotheses in this setting relate to a greater contribution of thrombus to the initiation of coronary occlusion (18) and impaired acute endogenous fibrinolytic capacity in smokers (27) . Both mechanisms could enhance the influence of the FXIII polymorphism. These results support that a combination of genetic and environmental factors could explain the broad heterogeneity of fibrinolytic therapy efficacy.
Interestingly, the influence of the FXIII Leu34 allele on fibrinolytic therapy was similar in the three main populations analyzed in our study, even after adjusting for several possible confounders. This is relevant because the prothrombotic role of this polymorphism has been suggested to be different in the three populations (11) (12) (13) (14) 17) . 
